Johnson & Johnson Announces Satisfaction of Regulatory Clearances Condition for its Proposed Acquisition of Mentor Corporation
January 15 2009 - 1:00PM
PR Newswire (US)
NEW BRUNSWICK, N.J., Jan. 15 /PRNewswire-FirstCall/ -- Johnson
& Johnson (NYSE:JNJ) today announced that all applicable
foreign antitrust and similar regulatory clearances required for
its cash tender offer to purchase all outstanding shares of common
stock of Mentor Corporation (NYSE:MNT) were obtained, or the
relevant waiting periods for clearance have expired. Johnson &
Johnson, through its wholly owned subsidiary, Maple Merger Sub,
Inc., initiated the tender offer on Dec. 1, 2008. The tender offer
will expire at 5:00 p.m. (Eastern time) on Jan. 16, 2009, unless
extended. The condition to the tender offer relating to clearance
under the Hart-Scott-Rodino Antitrust Improvements Act has also
been satisfied. The depositary for the tender offer has advised
Johnson & Johnson that, as of 12:00 p.m. (Eastern time) today,
a total of approximately 4,094,627 shares of Mentor common stock
were validly tendered and not withdrawn (including approximately
76,973 shares subject to guaranteed delivery procedures),
representing approximately 12.1% of Mentor's outstanding common
stock. Upon the successful closing of the tender offer,
shareholders of Mentor will receive $31.00 in cash for each share
of Mentor common stock tendered in the tender offer, without
interest and less any required withholding taxes. Following the
completion of the acquisition, it is expected that Mentor will
operate as a stand-alone business unit reporting through ETHICON,
Inc., a Johnson & Johnson company. Upon closing, the
transaction is expected to have a dilutive impact to Johnson &
Johnson's 2009 earnings per share of approximately $0.03 - $0.05.
This amount will be reflected as part of Johnson & Johnson's
earnings guidance, which will be provided Jan. 20, 2009. About
Johnson & Johnson Caring for the world, one person at a time
... inspires and unites the people of Johnson & Johnson. We
embrace research and science -- bringing innovative ideas, products
and services to advance the health and well-being of people. Our
119,400 employees at more than 250 Johnson & Johnson companies
work with partners in health care to touch the lives of over a
billion people every day, throughout the world. Additional
Information This press release is neither an offer to purchase nor
a solicitation of an offer to sell shares of Mentor Corporation.
Johnson & Johnson and Maple Merger Sub, Inc. have filed a
tender offer statement with the Securities and Exchange Commission
("SEC"), and have mailed an offer to purchase, forms of letter of
transmittal and related documents to Mentor shareholders. Mentor
has filed with the SEC, and has mailed to Mentor shareholders, a
solicitation/recommendation statement on Schedule 14D-9. These
documents contain important information about the tender offer and
shareholders of Mentor are urged to read them carefully. These
documents are available at no charge at the SEC's website at
http://www.sec.gov/. The tender offer statement and the related
materials may be obtained for free by directing a request by mail
to Georgeson Inc., 199 Water Street, New York, New York 10038 or by
calling toll-free (800) 213-0475 or (800) 445-1790. In addition, a
copy of the offer to purchase, letter of transmittal and certain
other related tender offer documents may be obtained free of charge
by directing a request to Johnson & Johnson at
http://www.jnj.com/, or Johnson & Johnson, One Johnson &
Johnson Plaza, New Brunswick, New Jersey 08933, Attn: Corporate
Secretary's Office. DATASOURCE: Johnson & Johnson CONTACT:
Press, Jeffrey J. Leebaw, +1-732-524-3350, or mobile,
+1-732-642-6608, or Bill Price, +1-732-524-6623, or mobile,
+1-732-668-3735, or Investors, Louise Mehrotra, +1-732-524-6491, or
Stan Panasewicz, +1-732-524-2524 Web Site: http://www.jnj.com/
Copyright
Mentor (NYSE:MNT)
Historical Stock Chart
From Jan 2025 to Feb 2025
Mentor (NYSE:MNT)
Historical Stock Chart
From Feb 2024 to Feb 2025